期刊文献+

DPP-4抑制剂在2型糖尿病中的研究进展 被引量:8

原文传递
导出
摘要 2型糖尿病是一种慢性进展性疾病,诊断初期患者的胰岛β细胞功能即损失50%以上。肠促胰岛激素效应的发现和应用是近年来糖尿病治疗方面较新的研究领域之一,它是人类进食后由肠道内分泌L细胞分泌的一类激素,主要包括胰升糖素样肽1(GLP-1)和葡萄糖依赖性促胰岛素分泌多肽(GIP),可以帮助机体产生部分餐后胰岛素效应。
作者 周丹 徐焱成
出处 《临床内科杂志》 CAS 2013年第1期68-70,共3页 Journal of Clinical Internal Medicine
  • 相关文献

参考文献17

  • 1Chen SJ,Jiaang WT. Current advances and therapeutic potential of a-gents targeting dipeptidyl peptidase-IV,-II,8/9 and fibroblast actionprotein. Curr Top Med Chem,2011 ,11:1447-1463. 被引量:1
  • 2Azuma K,Radikova Z,Mancino J,et al. Measurements of islet functionand glucose metabolism with the DPP-4 inhibitor vildagliptin in patientswith type 2 diabetes. Clin Endocrinol Metab,2008 ,93 :459-464. 被引量:1
  • 3Ayala JE,Bracy DP,Hansotia T,et al. Insulin action in the donble in-cretin receptor knockout mouse. Diabetes,2008,57:288-297. 被引量:1
  • 4Lamont BJ, Drucker DJ. Differential antidiabetic ef? cacy of incretin ag-onists versus DPP-4 inhibition in high fat fed mice. Diabetes,2008,57:190-198. 被引量:1
  • 5Dobrian AD,Ma Q,Lindsay JW,et al. Dipeptidyl peptidase IV inhibitorsitagliptin reduces local inflammation in adipose tissue and in pancreaticislets of obese mice. Endocrinology and metabolism,2011,300:410-421. 被引量:1
  • 6Chinda K,Palee S,Surinkaew S,et al. Cardioprotective effect of dipepti-dyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardi-ol,2012,26: Epub ahead of print. 被引量:1
  • 7Pi-Sunver FX, Schweiser A, Mills D, el al. Efficacy and tolerability ofvildagliptin monotherapy in drug-naive patients with type 2 diabetes. Di-abetes Res Clin Pract ,2007,76 : 132-138. 被引量:1
  • 8Schweizer A, Dejager S, Bosi E, et al. Comparison of vildagliptin andmetformin monotherapy in elderly patients with type 2 diabetes : a 24-week ,double-blind, randomized trial. Diabetes Obes Metab, 2009 ,11:804-812. 被引量:1
  • 9Rosenstock J,Aguilar-Salinas C,Klein E, et al. Effect of saxagliptinmonotherapy in treatment-naive patients with type 2 diabetes. Curt MedRes 0pin,2009,25 :2401-2411. 被引量:1
  • 10SeekT,Nauck M,Sheng D,et al. Safety and efficacy of treatment withsitagliptin or glipizide in patients with type 2 diabetes inadequately con-trolled on metformin : a 2 year study. Int J Clin Pract, 2011,64:562-576. 被引量:1

同被引文献65

  • 1汪寅章.2型糖尿病临床诊断标准及口服降血糖药现状[J].解放军保健医学杂志,1999,1(2):1-3. 被引量:25
  • 2Lehy JL. Pathogenesis of Type 2 diabetesmellitus. Arch Med Res, 2005, 36 : 197-209. 被引量:1
  • 3Azuma K, Radikova Z, Maneino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vilda-gliptin in patients with type 2 diabetes. J Chin Endocrinol Metab,2008, 93:459-464. 被引量:1
  • 4Bosehmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-I V inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. Clin Endocrinol Metab ,2009,94:846-852. 被引量:1
  • 5Ivanon KP,Mychka VB. Perspectives of impaired glucose tolerance man- agement in patients with metabolic syndrome. Cardiovase Ther Preven- tion,2011,10:77-82. 被引量:1
  • 6Van Poppel PC, Netea MG ,Smits P ,et al. ViIdagliptin improves endothe- lium-dependent vasodilatationin type 2 diabetes. Diabetes Care, 2011, 34 : 2072 -2077. 被引量:1
  • 7Ahren B. Emerging dipeptidyl peptidnse-4 inhibitors for the treatment of diabetes. Emerging Drugs ,2008,13 : 593-607. 被引量:1
  • 8Nauck M, Meininger G, Sheng D,et al. Efficacy and u f the safety of the dipep tidyl peptidaae-4 inhibitor, sitagliptin, compared to the sulphony- hrea in patients with type 2 diabetes in adequately controlled on met- formin alone : a randomized double-blind, non--infedofity trial. Diabetes Obes-Metah ,2007,9 : 194-205. 被引量:1
  • 9Shaw JE,Sicree RA,Zimmet PZ.Global estimates of the prevalence of diabetes for 2010 and 2030[J].Diabetes Res Clin Pract,2010,87(1):4-14. 被引量:1
  • 10Baetta R,Corsini A.Pharmacology of dipeptidyl peptidase-4 inhibitors:similarities and differences[J].Drugs,2011,71 (11):1441-1467. 被引量:1

引证文献8

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部